The Pharmacy Times® Women’s Health resource center provides clinical news and articles, pertaining to women’s wellness, nutrition, fitness, weight loss, and answers to other potentially more intimate questions.
What can we help you find?
Officials from the FDA have allowed ObsEva to begin enrolling patients in IMPLANT 3, the U.S. pivotal Phase 3 clinical trial in nolasiban in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF).
The injection’s active ingredient, 17α hydroxyprogesterone caproate (also known as 17P), is currently the only approved treatment for pregnant women who have had a prior spontaneous preterm birth.
Although 62% of the first professional degrees in pharmacy were awarded to women in 2017-2018,1 there are only about half as many female pharmacy owners as there are women graduating from pharmacy school.
The newly approved therapy is equivalent to AstraZeneca Pharmaceuticals’ Faslodex injection, 250mg/5mL.
Due to the large number of people affected, chlamydia has become a global health concern.
Attendees at the McKesson ideaShare had the chance to hear about women pharmacists and the challenges, successes, and opportunities they have in a session presented by Suzanne Soliman, PharmD.
The effectiveness and safety of bremelanotide were studied in a pair of 24-week, randomized, double-blind, placebo-controlled trials in 1247 premenopausal women with acquired, generalized HSDD.
A progestin-only pill, this estrogen-free oral contraceptive is intended as a 24 active and 4 inactive tablet dosing regimen.
Contraceptives are both a popular and effective birth control method, and Medicaid fully covers them for its beneficiaries.
Uncontrolled diabetes in pregnancy can lead to preeclampsia, cesarean delivery, preterm delivery, significant overgrowth in the child, and congenital defects.
This report revealed that in 2016, an estimated 3900 of 4200 or 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women.
The commercial availability of Bijuva offers an FDA approved alternative to marketed synthetic hormones or individual estrogen and progesterone products that have not been FDA-approved for combination use.